Purchase this article with an account.
J. Guerrero-Naranjo, M. A. Martinez-Castellanos, R. V. Chan, V. Morales-Canton; Topical Anesthesia in Antiangiogenic Therapy for Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2810.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The aim of the present study is to recorde the use of topical anesthesia in the treatment with antiangiogenic therapy for retinopathy of prematurity
We included patients treated in the NICU or in the office. All used tetracaine eye drops before the intravitreal injection of bevacizumab or ranibizumab under aseptic conditions. We measured with the premature infant pain profile (PIPP)
We included 18 eyes of 9 preterm patients that underwent antiangiogenic therapy for the treatment of retinopathy of prematurity, the PIPP measured in a range from 5 to 12 in a scale 0-21, None of the patients need intrvenous or subcuntaneous sedation, any of the patients presented complications due to anesthesia.
Topical anesthesia may be an option for the treatment of ROP with antiangiogenic therapy avoiding complications of general anesthesia or sedation.
Clinical Trial: :
This PDF is available to Subscribers Only